Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach

MLA

Roeker, Lindsey E., et al. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-Driven Approach. July 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........431153d99fa86cd3a2521cd6ee3852fd&authtype=sso&custid=ns315887.

APA

Roeker, L. E., Feldman, T. A., Soumerai, J. D., Falco, V., Panton, G., Dorsey, C., Zelenetz, A. D., Falchi, L., Park, J. H., Straus, D. J., Velasquez, C. P., Lebowitz, S., Fox, Y., Battiato, K., Laudati, C., Thompson, M. C., McCarthy, E., Kdiry, S., Martignetti, R., … Mato, A. R. (2022). Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach.

Chicago

Roeker, Lindsey E., Tatyana A. Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey, Andrew D. Zelenetz, et al. 2022. “Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-Driven Approach,” July. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........431153d99fa86cd3a2521cd6ee3852fd&authtype=sso&custid=ns315887.